Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma

Journal of Internal Medicine

Volumn 257, Issue 4, 2005, Pages 367-373

  Gianni, S ^a   Cecchetto, A ^a   Altavilla, G ^a   Ragazzi, R ^a   Bertazzo, M ^a   De Giorgio, M ^a   Baldan, A ^a   Fagiuoli, S ^a   Farinati, Fabio ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Biological neoplastic markers; Hepatocellular carcinoma; Prognostic factors

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 16244422974     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01460.x     Document Type: Article

References (31)

1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107.
2. Okuda K, Ohtsuki T, Obata H et al. Natural history of HCC and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
3. Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998; 83: 2302-11.
4. Herrero JI, Sangro B, Quiroga J et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 631-6.
5. Llad L, Virgili J, Figueras J et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50-7.
6. CLIP Group. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-5.
7. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 2266-73.
8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
9. Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Eur J Cancer Prev 2001; 10: 111-5.
10. Puisieux A, Ozturk M. p53 and hepatocellular carcinoma. Pathol Biol 1997; 45: 864-70.
11. Itoh H, Shiro T, Seki T et al. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 2000; 6: 137-142.
12. Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-751.
13. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392.
14. Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-51.
15. Tang ZY, Qin LX, Wang XM et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J 1998; 111: 313-8.
16. Ramsey WH, Wu GY. Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis 1995; 13: 81-91.
17. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
18. Livraghi T. Role of percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Dig Dis 2001; 19: 292-300.
19. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
20. CLIP Group (Cancer of the Liver Italian Program). Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998; 352: 17-20.
21. Villa E, Ferretti I, Grottola A et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 881-5.
22. Lygidakis NJ, Tygat GNJ. Hepatobiliary and pancreatic malignancies. Diagnosis, medical and surgical management. Ed Micarelli 1990; 3: 26-7.
23. Endo K, Terada D. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationship with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000; 32: 78-84.
24. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Salsho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 1998; 45: 1214-20.
25. Molmenti EP, Klintmann GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8: 736-48.
26. Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. Hepatogastroenterology 2002; 49: 7-11.
27. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-30.
28. Nzeako UC, Goodamn ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and non-cirrhotic livers. A clinico-pathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65-75.
29. Lauwers GY, Terris B, Balis UJ et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002; 26: 25-34.
30. Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutation as an indicator of biologic behaviour of recurrent hepatocellular carcinomas. Surg Today 1999; 29: 849-855.
31. Sheen IS, Jeng KS, Wu Jy. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003; 9: 1202-7.